Buscar
01/12/2023
Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up.
Papp KA, Blauvelt A, Puig L, Ohtsuki M, Beissert S, Gooderham M, Amin AZ, Liu J, Wu T, Azam T, Stakias V, Espaillat R, Sinvhal R, Soliman AM, Pang Y, Chen MM, Lebwohl MG. Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up.. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2023; 89(6)DOI:10.1016/j.jaad.2023.07.1024. PMID:37553030. IF:12.800(Q1/1D).
01/12/2023
Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24-28 and 48-52 weeks.
Egeberg A, Kristensen LE, Puig L, Rich P, Smith SD, Garrelts A, See K, Holzkaemper T, Fotiou K, Schuster C. Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24-28 and 48-52 weeks.. JOURNAL OF DERMATOLOGICAL TREATMENT. 2023; 34(1)DOI:10.1080/09546634.2023.2263108. PMID:37781881. IF:2.900(Q2/4D).
01/11/2023
[[Translated Article]]Race, Ethnicity, and Ancestry: A Short Review and Proposal for Consistent Classifications in Dermatology.
Puig L. [[Translated Article]]Race, Ethnicity, and Ancestry: A Short Review and Proposal for Consistent Classifications in Dermatology.. Actas Dermo-Sifiliograficas. 2023; 114(10)DOI:10.1016/j.ad.2023.09.020. PMID:37778620. IF:(Q/D).
01/10/2023
Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review.
Girolomoni G, Savage L, Gisondi P, Svensson Å, Mahé E, Augustin M, Puig L. Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review.. Dermatology and Therapy. 2023; 13(10)DOI:10.1007/s13555-023-01014-x. PMID:37710078. IF:3.500(Q1/3D).
01/10/2023
The journey of patients with skin diseases from the first consultation to the diagnosis in a representative sample of the European general population from the EADV burden of skin diseases study.
Richard MA, Paul C, Nijsten T, Gisondi P, Salavastru C, Taieb C, Stratigos A, Trakatelli M, Puig L. The journey of patients with skin diseases from the first consultation to the diagnosis in a representative sample of the European general population from the EADV burden of skin diseases study.. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; 37 Suppl 7DOI:10.1111/jdv.18916. PMID:37806003. IF:8.500(Q1/1D).
01/10/2023
Public perception of dermatologists in Europe: Results from a population-based survey
Richard MA, Paul C, Nijsten T, Gisondi P, Salavastru C, Taieb C, Trakatelli M, Puig L, Stratigos A. Public perception of dermatologists in Europe: Results from a population-based survey. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; 37 Suppl 7DOI:10.1111/jdv.18988. PMID:37806001. IF:8.500(Q1/1D).
01/10/2023
Quality of life and stigmatization in people with skin diseases in Europe: A large survey from the 'burden of skin diseases' EADV project.
Gisondi P, Puig L, Richard MA, Paul C, Nijsten T, Taieb C, Stratigos A, Trakatelli M, Salavastru C. Quality of life and stigmatization in people with skin diseases in Europe: A large survey from the 'burden of skin diseases' EADV project.. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; 37 Suppl 7DOI:10.1111/jdv.18917. PMID:37806002. IF:8.500(Q1/1D).
01/09/2023
A concept for integrated care pathways for atopic dermatitis-A GA(2) LEN ADCARE initiative.
Zuberbier T, Abdul Latiff A, Aggelidis X, Augustin M, Balan RG, Bangert C, Beck L, Bieber T, Bernstein JA, Bertolin Colilla M, Berardi A, Bedbrook A, Bindslev-Jensen C, Bousquet J, de Bruin-Weller M, Bruscky D, Buyuktiryaki B, Canonica GW, Castro C, Chanturidze N, Chong-Neto HJ, Chu CY, Chularojanamontri L, Cork M, Criado RFJ, Barredo LC, Custovic A, Darsow U, Emurlai A, de Pablo A, Del Giacco S, Girolomoni G, Deleva Jovanova T, Deleuran M, Douladiris N, Duarte B, Dubakiene R, Eller E, Engel-Yeger B, Ensina LF, Filho NR, Flohr C, Fomina D, Francuzik W, Galimberti ML, Giménez-Arnau AM, Godse K, Mortz CG, Gotua M, Hide M, Hoetzenecker W, Hunzelmann N, Irvine A, Jack C, Kanavarou I, Katoh N, Kinaciyan T, Kocatürk E, Kulthanan K, Lapeere H, Lau S, Machado Forti Nastri M, Makris M, Mansour E, Marsland A, Morelo Rocha Felix M, Moschione Castro AP, Nettis E, Nicolas JF, Nosbaum A, Odemyr M, Papapostolou N, Parisi CAS, Paudel S, Peter J, Pokharel P, Puig L, Quint T, Ramon GD, Regateiro F, Ricci G, Rosario C, Sackesen C, Schmid-Grendelmeier P, Serra-Baldrich E, Siemens K, Smith C, Staubach P, Stevanovic K, Su-Kücük Ö, Sussman G, Tavecchio S, Teovska Mitrevska N, Thaci D, Toubi E, Traidl-Hoffmann C, Treudler R, Vadasz Z, van Hofman I, Ventura MT, Wang Z, Werfel T, Wollenberg A, Yang A, Weng Yew Y, Zhao Z, Zwiener R, Worm M. A concept for integrated care pathways for atopic dermatitis-A GA(2) LEN ADCARE initiative.. Clinical and Translational Allergy. 2023; 13(9)DOI:10.1002/clt2.12299. PMID:37746794. IF:4.600(Q2/3D).